Monday, May 12, 2014

Update: CPIC ivacaftor-CFTR guideline

The CPIC guideline for ivacaftor treatment based on CFTR genotype has been updated on PharmGKB, in light of changes to the FDA-approved drug label.

Originally, ivacaftor was indicated only in patients with the G551D variant. This has now been extended to other variants that result in CFTR gating defects:

> View the updated CPIC ivacaftor-CFTR guideline.
Figure 1: Treatment algorithm for clinical use of ivacaftor for cystic fibrosis patients based on CFTR genotype.